18 February 2025 - Biocon announced today that the European Commission granted marketing authorisation in the European Union for Yesintek, a biosimilar of ustekinumab.

Yesimtek is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn’s disease.

Read Biocon press release